Quizartinib
Quizartinib is an oral targeted therapy that inhibits the FLT3 receptor tyrosine kinase, which is commonly mutated in acute myeloid leukemia (AML). It is specifically indicated for adult patients with relapsed or refractory FLT3-ITD positive AML. By blocking FLT3 signaling, quizartinib helps suppress the growth and survival of leukemic cells that depend on this pathway.
Quizartinib is an FLT3 inhibitor used to treat adults with relapsed or refractory FLT3-ITD positive acute myeloid leukemia.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01EX11
- RxNorm
- 2643048
- Generic
- Quizartinib
- Class
- atc-l01
- Brands
- Vanflyta
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Quizartinib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) that harbors an FLT3-ITD mutation. FLT3-ITD (internal tandem duplication) is one of the most common genetic alterations in AML and is associated with a poorer prognosis.
Quizartinib is a small molecule that reversibly binds to the ATP-binding domain of FLT3 receptor tyrosine kinase, inhibiting its enzymatic activity. Both quizartinib and its major active metabolite AC886 potently inhibit FLT3, blocking downstream signaling pathways that promote cell proliferation and survival in FLT3-mutant leukemia cells.
Quizartinib is an oral medication typically taken once daily. Common adverse effects may include myelosuppression, infections, and cardiac effects including QT prolongation. Treatment should be initiated by physicians experienced in managing AML. Genetic testing for FLT3-ITD mutation status is required prior to treatment initiation.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy